A 10-year survival update on early-stage extranodal natural killer/T-cell lymphoma with 'sandwich' therapy

Acta Oncol. 2022 May;61(5):611-614. doi: 10.1080/0284186X.2022.2044516. Epub 2022 Feb 28.

Authors

Chunli Yang¹, Li Zhang², Ming Jiang³, Li Xie³, Hong Zhang³, Weiping Liu⁴, Wenyan Zhang⁴, Sha Zhao⁴, Liqun Zou³

Affiliations

¹ State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
² National Cancer Center/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
³ Department of Oncology, West China Hospital of Sichuan University, Chengdu, China.
⁴ Department of Pathology, West China Hospital of Sichuan University, Chengdu, China.

PMID: 35225152
DOI: 10.1080/0284186X.2022.2044516

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Humans
Killer Cells, Natural
Lymphoma, T-Cell*
Prognosis